| Year |
Citation |
Score |
| 2024 |
Chesler L, Schlieve C, Goldenberg DD, Kenney A, Kim G, McMillan A, Matthay KK, Rowitch D, Weiss WA. Editor's Note: Inhibition of Phosphatidylinositol 3-Kinase Destabilizes Mycn Protein and Blocks Malignant Progression in Neuroblastoma. Cancer Research. 84: 3311. PMID 39350668 DOI: 10.1158/0008-5472.CAN-24-2888 |
0.47 |
|
| 2024 |
Saldana-Guerrero IM, Montano-Gutierrez LF, Boswell K, Hafemeister C, Poon E, Shaw LE, Stavish D, Lea RA, Wernig-Zorc S, Bozsaky E, Fetahu IS, Zoescher P, Pötschger U, Bernkopf M, Wenninger-Weinzierl A, ... ... Chesler L, et al. A human neural crest model reveals the developmental impact of neuroblastoma-associated chromosomal aberrations. Nature Communications. 15: 3745. PMID 38702304 DOI: 10.1038/s41467-024-47945-7 |
0.712 |
|
| 2023 |
Ferguson KM, Gillen SL, Chaytor L, Poon E, Marcos D, Gomez RL, Woods LM, Mykhaylechko L, Elfari L, Martins da Costa B, Jamin Y, Carroll JS, Chesler L, Ali FR, Philpott A. Palbociclib releases the latent differentiation capacity of neuroblastoma cells. Developmental Cell. PMID 37734383 DOI: 10.1016/j.devcel.2023.08.028 |
0.367 |
|
| 2021 |
Tsakaneli A, Carregari VC, Morini M, Eva A, Cangemi G, Chayka O, Makarov E, Bibbò S, Capone E, Sala G, De Laurenzi V, Poon E, Chesler L, Pieroni L, Larsen MR, et al. MYC regulates metabolism through vesicular transfer of glycolytic kinases. Open Biology. 11: 210276. PMID 34847775 DOI: 10.1098/rsob.210276 |
0.305 |
|
| 2021 |
Urban-Wójciuk Z, Graham A, Barker K, Kwok C, Sbirkov Y, Howell L, Campbell J, Woster PM, Poon E, Petrie K, Chesler L. The biguanide polyamine analog verlindamycin promotes differentiation in neuroblastoma via induction of antizyme. Cancer Gene Therapy. PMID 34522028 DOI: 10.1038/s41417-021-00386-6 |
0.326 |
|
| 2021 |
Shrestha S, Morcavallo A, Gorrini C, Chesler L. Biological Role of MYCN in Medulloblastoma: Novel Therapeutic Opportunities and Challenges Ahead. Frontiers in Oncology. 11: 694320. PMID 34195095 DOI: 10.3389/fonc.2021.694320 |
0.3 |
|
| 2021 |
Ingley KM, Hughes D, Hubank M, Lindsay D, Plumb A, Cox R, Chesler L, Strauss SJ. Durable response to serial tyrosine kinase inhibitors (TKIs) in an adolescent with metastatic TFG-ROS1 fusion positive Inflammatory Myofibroblastic Tumor (IMT). Lung Cancer (Amsterdam, Netherlands). PMID 34059352 DOI: 10.1016/j.lungcan.2021.05.024 |
0.32 |
|
| 2021 |
Dubiella C, Pinch BJ, Koikawa K, Zaidman D, Poon E, Manz TD, Nabet B, He S, Resnick E, Rogel A, Langer EM, Daniel CJ, Seo HS, Chen Y, Adelmant G, ... ... Chesler L, et al. Sulfopin is a covalent inhibitor of Pin1 that blocks Myc-driven tumors in vivo. Nature Chemical Biology. PMID 33972797 DOI: 10.1038/s41589-021-00786-7 |
0.398 |
|
| 2021 |
Roeschert I, Poon E, Henssen AG, Garcia HD, Gatti M, Giansanti C, Jamin Y, Ade CP, Gallant P, Schülein-Völk C, Beli P, Richards M, Rosenfeldt M, Altmeyer M, Anderson J, ... ... Chesler L, et al. Combined inhibition of Aurora-A and ATR kinase results in regression of -amplified neuroblastoma. Nature Cancer. 2: 312-326. PMID 33768209 DOI: 10.1038/s43018-020-00171-8 |
0.345 |
|
| 2021 |
Morcavallo A, Barker K, Adachi T, Boult JKR, Kwok C, da Silva PBG, Okonechnikov K, Hitchen L, Robinson SP, Clifford SC, Pfister SM, Kawauchi D, Chesler L. TMOD-03. A NOVEL MB GR3 TRANSGENIC MOUSE MODEL IS GENERATED BY MYCN AND P53 DEFECTS IN VENTRICULAR ZONE PROGENITORS. Neuro-Oncology. 23: i36-i36. DOI: 10.1093/NEUONC/NOAB090.144 |
0.333 |
|
| 2020 |
Poon E, Liang T, Jamin Y, Walz S, Kwok C, Hakkert A, Barker K, Urban Z, Thway K, Zeid R, Hallsworth A, Box G, Ebus ME, Licciardello MP, Sbirkov Y, ... ... Chesler L, et al. Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma. The Journal of Clinical Investigation. PMID 33016930 DOI: 10.1172/JCI134132 |
0.329 |
|
| 2020 |
Caravagna G, Heide T, Williams MJ, Zapata L, Nichol D, Chkhaidze K, Cross W, Cresswell GD, Werner B, Acar A, Chesler L, Barnes CP, Sanguinetti G, Graham TA, Sottoriva A. Subclonal reconstruction of tumors by using machine learning and population genetics. Nature Genetics. 52: 898-907. PMID 32879509 DOI: 10.1038/S41588-020-0675-5 |
0.322 |
|
| 2020 |
George SL, Lorenzi F, King D, Hartlieb S, Campbell J, Pemberton H, Toprak UH, Barker K, Tall J, da Costa BM, van den Boogaard ML, Dolman MEM, Molenaar JJ, Bryant HE, Westermann F, ... ... Chesler L, et al. Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma. Ebiomedicine. 59: 102971. PMID 32846370 DOI: 10.1016/J.Ebiom.2020.102971 |
0.301 |
|
| 2020 |
Moreno L, Barone G, DuBois SG, Molenaar J, Fischer M, Schulte J, Eggert A, Schleiermacher G, Speleman F, Chesler L, Geoerger B, Hogarty MD, Irwin MS, Bird N, Blanchard GB, et al. Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma. European Journal of Cancer (Oxford, England : 1990). 136: 52-68. PMID 32653773 DOI: 10.1016/J.Ejca.2020.05.010 |
0.333 |
|
| 2020 |
Zormpas-Petridis K, Poon E, Clarke M, Jerome NP, Boult JKR, Blackledge MD, Carceller F, Koers A, Barone G, Pearson ADJ, Moreno L, Anderson J, Sebire N, McHugh K, Koh DM, ... Chesler L, et al. Noninvasive MRI native T1 mapping detects response to MYCN-targeted therapies in the Th-MYCN model of neuroblastoma. Cancer Research. PMID 32595135 DOI: 10.1158/0008-5472.Can-20-0133 |
0.353 |
|
| 2020 |
King D, Li XD, Almeida GS, Kwok C, Gravells P, Harrison D, Burke S, Hallsworth A, Jamin Y, George S, Robinson SP, Lord CJ, Poon E, Yeomanson D, Chesler L, et al. MYCN expression induces replication stress and sensitivity to PARP inhibition in neuroblastoma. Oncotarget. 11: 2141-2159. PMID 32577161 DOI: 10.18632/Oncotarget.27329 |
0.379 |
|
| 2020 |
Fultang L, Booth S, Yogev O, Martins da Costa B, Tubb V, Panetti S, Stavrou V, Scarpa U, Jankevics A, Lloyd G, Southam AD, Lee SP, Dunn W, Chesler L, Mussai FJ, et al. Metabolic engineering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activity. Blood. PMID 32573723 DOI: 10.1182/Blood.2019004500 |
0.304 |
|
| 2020 |
Garancher A, Suzuki H, Haricharan S, Chau LQ, Masihi MB, Rusert JM, Norris PS, Carrette F, Romero MM, Morrissy SA, Skowron P, Cavalli FMG, Farooq H, Ramaswamy V, Jones SJM, ... ... Chesler L, et al. Tumor necrosis factor overcomes immune evasion in p53-mutant medulloblastoma. Nature Neuroscience. PMID 32424282 DOI: 10.1038/S41593-020-0628-4 |
0.429 |
|
| 2020 |
George SL, Parmar V, Lorenzi F, Marshall LV, Jamin Y, Poon E, Angelini P, Chesler L. Novel therapeutic strategies targeting telomere maintenance mechanisms in high-risk neuroblastoma. Journal of Experimental & Clinical Cancer Research : Cr. 39: 78. PMID 32375866 DOI: 10.1186/S13046-020-01582-2 |
0.429 |
|
| 2020 |
Franco-Luzón L, González-Murillo Á, Alcántara-Sánchez C, García-García L, Tabasi M, Huertas AL, Chesler L, Ramírez M. Systemic oncolytic adenovirus delivered in mesenchymal carrier cells modulate tumor infiltrating immune cells and tumor microenvironment in mice with neuroblastoma. Oncotarget. 11: 347-361. PMID 32064039 DOI: 10.18632/Oncotarget.27401 |
0.417 |
|
| 2020 |
Garancher A, Suzuki H, Haricharan S, Masihi MB, Rusert JM, Norris PS, Carrette F, Romero MM, Morrissy SA, Skowron P, Cavalli FMG, Farooq H, Ramaswamy V, Morcavallo A, Henderson JJ, ... ... Chesler L, et al. Abstract IA11: Overcoming immune evasion in pediatric brain tumors Cancer Research. 80. DOI: 10.1158/1538-7445.Pedca19-Ia11 |
0.432 |
|
| 2020 |
Llargués-Sistac G, Lindsey J, Swartz S, Selby M, Morcavallo A, Bailey S, Chesler L, Lord CJ, Williamson D, Clifford SC. MBRS-57. IDENTIFICATION OF MYC-DEPENDENT THERAPEUTIC VULNERABILITIES FOR TARGETING GROUP 3 MEDULLOBLASTOMA Neuro-Oncology. 22: iii407-iii408. DOI: 10.1093/neuonc/noaa222.562 |
0.356 |
|
| 2019 |
Tucker ER, Poon E, Chesler L. Targeting MYCN and ALK in resistant and relapsing neuroblastoma. Cancer Drug Resistance (Alhambra, Calif.). 2: 803-812. PMID 35582571 DOI: 10.20517/cdr.2019.009 |
0.321 |
|
| 2019 |
Li J, Zormpas-Petridis K, Boult JK, Reeves EL, Heindl A, Vinci M, Lopes F, Cummings C, Springer CJ, Chesler L, Jones C, Bamber JC, Yuan Y, Sinkus R, Jamin Y, et al. Investigating the Contribution of Collagen to the Tumor Biomechanical Phenotype with Non-invasive Magnetic Resonance Elastography. Cancer Research. PMID 31604713 DOI: 10.1158/0008-5472.Can-19-1595 |
0.301 |
|
| 2019 |
Yogev O, Almeida GS, Barker KT, George SL, Kwok C, Campbell J, Zarowiecki M, Kleftogiannis D, Smith LM, Hallsworth A, Berry P, Möcklinghoff T, Webber HT, Danielson LS, Buttery B, ... ... Chesler L, et al. In vivo modelling of chemo-resistant neuroblastoma provides new insights into chemo-refractory disease and metastasis. Cancer Research. PMID 31405846 DOI: 10.1158/0008-5472.Can-18-2759 |
0.496 |
|
| 2019 |
Zormpas-Petridis K, Jerome NP, Blackledge MD, Carceller F, Poon E, Clarke M, McErlean CM, Barone G, Koers A, Vaidya SJ, Marshall LV, Pearson ADJ, Moreno L, Anderson J, Sebire N, ... ... Chesler L, et al. MRI Imaging of the Hemodynamic Vasculature of Neuroblastoma Predicts Response to Anti-angiogenic Treatment. Cancer Research. PMID 30877107 DOI: 10.1158/0008-5472.Can-18-3412 |
0.318 |
|
| 2019 |
Watts E, Heidenreich D, Tucker E, Raab M, Strebhardt K, Chesler L, Knapp S, Bellenie B, Hoelder S. Designing Dual Inhibitors of Anaplastic Lymphoma Kinase (ALK) and Bromodomain-4 (BRD4) by Tuning Kinase Selectivity. Journal of Medicinal Chemistry. PMID 30789735 DOI: 10.1021/Acs.Jmedchem.8B01947 |
0.353 |
|
| 2019 |
Aldape K, Brindle KM, Chesler L, Chopra R, Gajjar A, Gilbert MR, Gottardo N, Gutmann DH, Hargrave D, Holland EC, Jones DTW, Joyce JA, Kearns P, Kieran MW, Mellinghoff IK, et al. Challenges to curing primary brain tumours. Nature Reviews. Clinical Oncology. PMID 30733593 DOI: 10.1038/S41571-019-0177-5 |
0.328 |
|
| 2019 |
Carreno G, Boult JKR, Apps JR, Gonzalez-Meljem JM, Haston S, Guiho R, Stache C, Danielson LS, Koers A, Smith LS, Virasami A, Panousopoulos L, Buchfelder M, Jacques TS, Chesler L, et al. SHH pathway inhibition is protumourigenic in adamantinomatous craniopharyngioma. Endocrine-Related Cancer. PMID 30645190 DOI: 10.1530/Erc-18-0538 |
0.433 |
|
| 2019 |
Garancher A, Suzuki H, Haricharan S, Masihi MB, Rusert JM, Norris PS, Carrette F, Romero MM, Morrissy SA, Skowron P, M.G. Cavalli F, Farooq H, Ramaswamy V, J.M. Jones S, Moore RA, ... ... Chesler L, et al. IMMU-03. TUMOR NECROSIS FACTOR OVERCOMES IMMUNE EVASION IN P53-MUTANT MEDULLOBLASTOMA Neuro-Oncology. 21: ii93-ii93. DOI: 10.1093/Neuonc/Noz036.124 |
0.344 |
|
| 2018 |
Fultang L, Gamble LD, Gneo L, Berry AM, Egan SA, De Bie F, Yogev O, Eden GL, Booth S, Brownhill S, Vardon A, McConville CM, Cheng PN, Norris MD, Etchevers HC, ... ... Chesler L, et al. Macrophage-derived IL-1β and TNF-α regulate arginine metabolism in neuroblastoma. Cancer Research. PMID 30545920 DOI: 10.1158/0008-5472.Can-18-2139 |
0.391 |
|
| 2018 |
Gonzalez Malagon SG, Lopez Muñoz AM, Doro D, Bolger TG, Poon E, Tucker ER, Adel Al-Lami H, Krause M, Phiel CJ, Chesler L, Liu KJ. Glycogen synthase kinase 3 controls migration of the neural crest lineage in mouse and Xenopus. Nature Communications. 9: 1126. PMID 29555900 DOI: 10.1038/S41467-018-03512-5 |
0.388 |
|
| 2018 |
Ferrucci V, de Antonellis P, Pennino FP, Asadzadeh F, Virgilio A, Montanaro D, Galeone A, Boffa I, Pisano I, Scognamiglio I, Navas L, Diana D, Pedone E, Gargiulo S, Gramanzini M, ... ... Chesler L, et al. Metastatic group 3 medulloblastoma is driven by PRUNE1 targeting NME1-TGF-β-OTX2-SNAIL via PTEN inhibition. Brain : a Journal of Neurology. PMID 29490009 DOI: 10.1093/Brain/Awy039 |
0.713 |
|
| 2018 |
Zeid R, Lawlor MA, Poon E, Reyes JM, Fulciniti M, Lopez MA, Scott TG, Nabet B, Erb MA, Winter GE, Jacobson Z, Polaski DR, Karlin KL, Hirsch RA, Munshi NP, ... ... Chesler L, et al. Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma. Nature Genetics. PMID 29379199 DOI: 10.1038/S41588-018-0044-9 |
0.35 |
|
| 2018 |
Ferrucci V, Antonellis Pd, Pennino FP, Asadzadeh F, Siciliano R, Virgilio A, Galeone A, Martino LD, Quaglietta L, Errico ME, Donofrio V, Picard D, Remke M, Chesler L, Johansson FK, et al. Mbrs-52. Targeting Prune-1 In A Gemm Of Metastatic Medulloblastoma: A Potential Route Of Inhibition For New Future Therapies Neuro-Oncology. 20: 139-139. DOI: 10.1093/Neuonc/Noy059.497 |
0.517 |
|
| 2017 |
Izquierdo E, Yuan L, George S, Hubank M, Jones C, Proszek P, Shipley J, Gatz SA, Stinson C, Moore AS, Clifford SC, Hicks D, Lindsey JC, Hill RM, Jacques TS, ... ... Chesler L, et al. Development of a targeted sequencing approach to identify prognostic, predictive and diagnostic markers in paediatric solid tumours. Oncotarget. 8: 112036-112050. PMID 29340109 DOI: 10.18632/Oncotarget.23000 |
0.362 |
|
| 2017 |
Moreno L, Caron H, Geoerger B, Eggert A, Schleiermacher G, Brock P, Valteau-Couanet D, Chesler L, Schulte JH, Preter K, Molenaar J, Schramm A, Eilers M, Maerken TV, Johnsen JI, et al. Accelerating Drug Development for Neuroblastoma - New Drug Development Strategy: An Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma Project. Expert Opinion On Drug Discovery. PMID 28604107 DOI: 10.1080/17460441.2017.1340269 |
0.319 |
|
| 2017 |
Tucker ER, Tall JR, Danielson LS, Gowan S, Jamin Y, Robinson SP, Banerji U, Chesler L. Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma. Molecular Oncology. PMID 28432815 DOI: 10.1002/1878-0261.12069 |
0.399 |
|
| 2017 |
Apps J, Carreno G, Boult J, Gutteridge A, Danielson L, Jani N, Tossell K, Forshew T, Hargrave D, Chesler L, Robinson S, Jacques T, Williams H, Martinez-Barbera JP. Molecular profiling and preclinical targeted therapeutic testing in adamantinomatous craniopharyngioma The Lancet. 389. DOI: 10.1016/S0140-6736(17)30418-X |
0.411 |
|
| 2016 |
Richards MW, Burgess SG, Poon E, Carstensen A, Eilers M, Chesler L, Bayliss R. Structural basis of N-Myc binding by Aurora-A and its destabilization by kinase inhibitors. Proceedings of the National Academy of Sciences of the United States of America. PMID 27837025 DOI: 10.1073/Pnas.1610626113 |
0.367 |
|
| 2016 |
Brockmann M, Poon E, Berry T, Carstensen A, Deubzer HE, Rycak L, Jamin Y, Thway K, Robinson SP, Roels F, Witt O, Fischer M, Chesler L, Eilers M. Small Molecule Inhibitors of Aurora-A Induce Proteasomal Degradation of N-Myc in Childhood Neuroblastoma. Cancer Cell. 30: 357-358. PMID 27505677 DOI: 10.1016/J.Ccell.2016.07.002 |
0.325 |
|
| 2016 |
Guan J, Tucker ER, Wan H, Chand D, Danielson LS, Ruuth K, El Wakil A, Witek B, Jamin Y, Umapathy G, Robinson SP, Johnson TW, Smeal T, Martinsson T, Chesler L, et al. The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN. Disease Models & Mechanisms. PMID 27483357 DOI: 10.1242/Dmm.024448 |
0.386 |
|
| 2016 |
Vaughan L, Clarke PA, Barker K, Chanthery Y, Gustafson CW, Tucker E, Renshaw J, Raynaud F, Li X, Burke R, Jamin Y, Robinson SP, Pearson A, Maira M, Weiss WA, ... ... Chesler L, et al. Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors. Oncotarget. PMID 27438153 DOI: 10.18632/Oncotarget.10544 |
0.799 |
|
| 2016 |
Pearson AD, Herold R, Rousseau R, Copland C, Bradley-Garelik B, Binner D, Capdeville R, Caron H, Carleer J, Chesler L, Geoerger B, Kearns P, Marshall LV, Pfister SM, Schleiermacher G, et al. Implementation of mechanism of action biology-driven early drug development for children with cancer. European Journal of Cancer (Oxford, England : 1990). 62: 124-131. PMID 27258969 DOI: 10.1016/J.Ejca.2016.04.001 |
0.319 |
|
| 2016 |
Yogev O, Barker K, Sikka A, Almeida GS, Hallsworth A, Smith LM, Jamin Y, Ruddle R, Koers A, Webber HT, Raynaud FI, Popov S, Jones C, Petrie K, Robinson SP, ... ... Chesler L, et al. p53 Loss in MYC-Driven Neuroblastoma Leads to Metabolic Adaptations Supporting Radioresistance. Cancer Research. 76: 3025-3035. PMID 27197232 DOI: 10.1158/0008-5472.Can-15-1939 |
0.442 |
|
| 2016 |
Guan J, Danielson L, Chand D, Jamin Y, Ruuth K, Tucker E, Umapathy G, Wakil AE, Witek B, Johnson TW, Smeal T, Chesler L, Palmer RH, Hallberg B. Abstract B12: The ALK inhibitor PF-06463922 shows significant response as a single agent in ALK/MYCN driven models of neuroblastoma Cancer Research. 76. DOI: 10.1158/1538-7445.Pedca15-B12 |
0.421 |
|
| 2015 |
Smith JR, Moreno L, Heaton SP, Chesler L, Pearson AD, Garrett MD. Novel pharmacodynamic biomarkers for MYCN protein and PI3K/AKT/mTOR pathway signaling in children with neuroblastoma. Molecular Oncology. PMID 26686971 DOI: 10.1016/J.Molonc.2015.11.005 |
0.381 |
|
| 2015 |
Dolman ME, Poon E, Ebus ME, den Hartog IJ, van Noesel CJ, Jamin Y, Hallsworth A, Robinson SP, Petrie K, Sparidans RW, Kok RJ, Versteeg R, Caron HN, Chesler L, Molenaar JJ. Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26202950 DOI: 10.1158/1078-0432.Ccr-15-0313 |
0.463 |
|
| 2015 |
Tucker ER, Danielson LS, Innocenti P, Chesler L. Tackling Crizotinib Resistance: The Pathway from Drug Discovery to the Pediatric Clinic. Cancer Research. 75: 2770-4. PMID 26122839 DOI: 10.1158/0008-5472.Can-14-3817 |
0.386 |
|
| 2015 |
Mussai F, Egan S, Hunter S, Webber H, Fisher J, Wheat R, McConville C, Sbirkov Y, Wheeler K, Bendle G, Petrie K, Anderson J, Chesler L, De Santo C. Neuroblastoma Arginase Activity Creates an Immunosuppressive Microenvironment That Impairs Autologous and Engineered Immunity. Cancer Research. PMID 26054597 DOI: 10.1158/0008-5472.Can-14-3443 |
0.378 |
|
| 2015 |
Cage TA, Chanthery Y, Chesler L, Grimmer M, Knight Z, Shokat K, Weiss WA, Gustafson WC. Downregulation of MYCN through PI3K Inhibition in Mouse Models of Pediatric Neural Cancer. Frontiers in Oncology. 5: 111. PMID 26029667 DOI: 10.3389/Fonc.2015.00111 |
0.763 |
|
| 2015 |
Cheung BB, Tan O, Koach J, Liu B, Shum MS, Carter DR, Sutton S, Po'uha ST, Chesler L, Haber M, Norris MD, Kavallaris M, Liu T, O'Neill GM, Marshall GM. Thymosin-β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma. Molecular Oncology. 9: 1484-500. PMID 25963741 DOI: 10.1016/J.Molonc.2015.04.005 |
0.408 |
|
| 2015 |
Ahmad Z, Jasnos L, Gil V, Howell L, Hallsworth A, Petrie K, Sawado T, Chesler L. Molecular and in vivo characterization of cancer-propagating cells derived from MYCN-dependent medulloblastoma. Plos One. 10: e0119834. PMID 25785590 DOI: 10.1371/Journal.Pone.0119834 |
0.529 |
|
| 2015 |
Hill RM, Kuijper S, Lindsey JC, Petrie K, Schwalbe EC, Barker K, Boult JK, Williamson D, Ahmad Z, Hallsworth A, Ryan SL, Poon E, Robinson SP, Ruddle R, Raynaud FI, ... ... Chesler L, et al. Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease. Cancer Cell. 27: 72-84. PMID 25533335 DOI: 10.1016/J.Ccell.2014.11.002 |
0.739 |
|
| 2015 |
Cage TA, Chanthery Y, Chesler L, Grimmer M, Knight Z, Shokat K, Weiss WA, Gustafson WC. Downregulation of MYCN through PI3K inhibition in mouse models of pediatric neural cancer Frontiers in Oncology. 5. DOI: 10.3389/fonc.2015.00111 |
0.716 |
|
| 2015 |
Healy JR, Schnepp RW, Hart LS, Raman P, Danielson L, Russell M, Khurana P, Gagliardi M, Kinsey RM, Wyce A, Barbash O, Tummino PJ, Chesler L, Maris JM. Abstract B34: Antitumor activity and sensitivity evaluation of novel BET inhibitors in neuroblastoma Molecular Cancer Research. 13. DOI: 10.1158/1557-3125.Myc15-B34 |
0.461 |
|
| 2015 |
Almeida GS, King P, Jamin Y, Hallsworth A, Webber H, Popov S, Pearson ADJ, Chesler L, Robinson SP. Abstract 491: Tumor response to cabozantinib in the TH-MYCN GEM model of neuroblastoma Cancer Research. 75: 491-491. DOI: 10.1158/1538-7445.Am2015-491 |
0.451 |
|
| 2015 |
Li J, Boult JKR, Vinci M, Popov S, Barker K, Ahmad Z, Jamin Y, Cummings C, Eccles SA, Bamber JC, Sinkus R, Chesler L, Jones C, Robinson SP. Abstract 1488:In vivomagnetic resonance elastography in pediatric brain tumor models Cancer Research. 75: 1488-1488. DOI: 10.1158/1538-7445.Am2015-1488 |
0.44 |
|
| 2014 |
Umapathy G, El Wakil A, Witek B, Chesler L, Danielson L, Deng X, Gray NS, Johansson M, Kvarnbrink S, Ruuth K, Schönherr C, Palmer RH, Hallberg B. The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma. Science Signaling. 7: ra102. PMID 25351247 DOI: 10.1126/Scisignal.2005470 |
0.37 |
|
| 2014 |
Moore NF, Azarova AM, Bhatnagar N, Ross KN, Drake LE, Frumm S, Liu QS, Christie AL, Sanda T, Chesler L, Kung AL, Gray NS, Stegmaier K, George RE. Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma. Oncotarget. 5: 8737-49. PMID 25228590 DOI: 10.18632/Oncotarget.2372 |
0.448 |
|
| 2014 |
Jamin Y, Glass L, Hallsworth A, George R, Koh DM, Pearson AD, Chesler L, Robinson SP. Intrinsic susceptibility MRI identifies tumors with ALKF1174L mutation in genetically-engineered murine models of high-risk neuroblastoma. Plos One. 9: e92886. PMID 24667968 DOI: 10.1371/Journal.Pone.0092886 |
0.364 |
|
| 2014 |
Barone G, Tweddle DA, Shohet JM, Chesler L, Moreno L, Pearson AD, Van Maerken T. MDM2-p53 interaction in paediatric solid tumours: preclinical rationale, biomarkers and resistance. Current Drug Targets. 15: 114-23. PMID 24387312 DOI: 10.2174/13894501113149990194 |
0.334 |
|
| 2014 |
Schnepp R, Hart L, Raman P, Danielson L, Gagliardi M, Kinsey R, Wyce A, Barbash O, Tummino P, Chesler L, Maris J. Abstract B75: Defining the antitumor activity and sensitivity profiles of BET inhibitors in neuroblastoma Cancer Research. 74. DOI: 10.1158/1538-7445.Pedcan-B75 |
0.472 |
|
| 2014 |
Hill RM, Kuijper S, Lindsey J, Schwalbe EC, Barker K, Boult J, Williamson D, Ahmad Z, Hallsworth A, Ryan S, Poon E, Robinson S, Ruddle R, Raynaud F, Howell L, ... ... Chesler L, et al. MYC and TP53 defects interact at medulloblastoma relapse to define rapidly progressive disease and can be targeted therapeutically Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-201 |
0.744 |
|
| 2014 |
Vaidyanathan G, Gururangan S, Bigner D, Zalutsky M, Morfouace M, Shelat A, Megan J, Freeman BB, Robinson S, Throm S, Olson JM, Li X, Guy KR, Robinson G, Stewart C, ... ... Chesler L, et al. MEDULLOBLASTOMA Neuro-Oncology. 16: i71-i96. DOI: 10.1093/Neuonc/Nou074 |
0.692 |
|
| 2013 |
Lastowska M, Al-Afghani H, Al-Balool HH, Sheth H, Mercer E, Coxhead JM, Redfern CP, Peters H, Burt AD, Santibanez-Koref M, Bacon CM, Chesler L, Rust AG, Adams DJ, Williamson D, et al. Identification of a neuronal transcription factor network involved in medulloblastoma development. Acta Neuropathologica Communications. 1: 35. PMID 24252690 DOI: 10.1186/2051-5960-1-35 |
0.334 |
|
| 2013 |
Barone G, Anderson J, Pearson AD, Petrie K, Chesler L. New strategies in neuroblastoma: Therapeutic targeting of MYCN and ALK. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 5814-21. PMID 23965898 DOI: 10.1158/1078-0432.Ccr-13-0680 |
0.384 |
|
| 2013 |
Brockmann M, Poon E, Berry T, Carstensen A, Deubzer HE, Rycak L, Jamin Y, Thway K, Robinson SP, Roels F, Witt O, Fischer M, Chesler L, Eilers M. Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma. Cancer Cell. 24: 75-89. PMID 23792191 DOI: 10.1016/J.Ccr.2013.05.005 |
0.402 |
|
| 2013 |
Petrie K, Field M, Ahmad Z, Dezfouli M, Barker K, Jeznach M, Glass L, Hallsworth A, Sbirkov Y, Womersley H, Zelent A, Jordan P, Akoulitchev A, Chesler L. Abstract LB-87: A novel epigenetic blood test to monitor minimal residual disease in high-risk neuroblastoma. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-87 |
0.414 |
|
| 2013 |
Jamin Y, Glass L, Hallsworth A, George RE, Koh D, Pearson ADJ, Chesler L, Robinson SP. Abstract 5037: Intrinsic susceptibility magnetic resonance imaging identifies tumors with ALKF1174L mutation in transgenic murine models of high-risk neuroblastoma. Cancer Research. 73: 5037-5037. DOI: 10.1158/1538-7445.Am2013-5037 |
0.401 |
|
| 2013 |
Brockmann M, Poon E, Chesler L, Eilers M. Abstract IA13: Targeting the dependence of N-Myc on interaction with Aurora-A with small molecules Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Pms-Ia13 |
0.466 |
|
| 2012 |
Walton MI, Eve PD, Hayes A, Valenti MR, De Haven Brandon AK, Box G, Hallsworth A, Smith EL, Boxall KJ, Lainchbury M, Matthews TP, Jamin Y, Robinson SP, Aherne GW, Reader JC, ... Chesler L, et al. CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 5650-61. PMID 22929806 DOI: 10.1158/1078-0432.Ccr-12-1322 |
0.367 |
|
| 2012 |
Berry T, Luther W, Bhatnagar N, Jamin Y, Poon E, Sanda T, Pei D, Sharma B, Vetharoy WR, Hallsworth A, Ahmad Z, Barker K, Moreau L, Webber H, Wang W, ... ... Chesler L, et al. The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma. Cancer Cell. 22: 117-30. PMID 22789543 DOI: 10.1016/J.Ccr.2012.06.001 |
0.473 |
|
| 2012 |
Swartling FJ, Savov V, Persson AI, Chen J, Hackett CS, Northcott PA, Grimmer MR, Lau J, Chesler L, Perry A, Phillips JJ, Taylor MD, Weiss WA. Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC. Cancer Cell. 21: 601-13. PMID 22624711 DOI: 10.1016/J.Ccr.2012.04.012 |
0.726 |
|
| 2012 |
Terrile M, Bryan K, Kuijper S, Chesler L, Stallings RL. Abstract 1426: MiRNA expression profiling of the murine GTML medulloblastoma model reveals similarities with human tumors and identifies novel candidate miRNAs Cancer Research. 72: 1426-1426. DOI: 10.1158/1538-7445.Am2012-1426 |
0.329 |
|
| 2011 |
Moreno L, Chesler L, Hargrave D, Eccles SA, Pearson AD. Preclinical drug development for childhood cancer. Expert Opinion On Drug Discovery. 6: 49-64. PMID 22646826 DOI: 10.1517/17460441.2011.537652 |
0.333 |
|
| 2011 |
Terrile M, Bryan K, Vaughan L, Hallsworth A, Webber H, Chesler L, Stallings RL. miRNA expression profiling of the murine TH-MYCN neuroblastoma model reveals similarities with human tumors and identifies novel candidate miRNAs. Plos One. 6: e28356. PMID 22164278 DOI: 10.1371/Journal.Pone.0028356 |
0.364 |
|
| 2011 |
Chesler L, Weiss WA. Genetically engineered murine models--contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma. Seminars in Cancer Biology. 21: 245-55. PMID 21958944 DOI: 10.1016/J.Semcancer.2011.09.011 |
0.536 |
|
| 2011 |
Faisal A, Vaughan L, Bavetsias V, Sun C, Atrash B, Avery S, Jamin Y, Robinson SP, Workman P, Blagg J, Raynaud FI, Eccles SA, Chesler L, Linardopoulos S. The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo. Molecular Cancer Therapeutics. 10: 2115-23. PMID 21885865 DOI: 10.1158/1535-7163.Mct-11-0333 |
0.463 |
|
| 2011 |
Jamin Y, Cullis ER, Vaughan L, Webber H, Boult JK, Baker LC, Dow-Mu K, Chesler L, Robinson SP. Abstract 5290: Imaging biomarkers of response to chemotherapy in neuroblastoma Cancer Research. 71: 5290-5290. DOI: 10.1158/1538-7445.Am2011-5290 |
0.402 |
|
| 2011 |
George RE, Luther W, Ahmad Z, Cullis ER, Webber H, Rodig S, Pearson AD, Chesler L. Abstract 4757: The ALK-F1174L mutation accelerates MYCN-driven tumorigenesis in a murine transgenic neuroblastoma model Cancer Research. 71: 4757-4757. DOI: 10.1158/1538-7445.Am2011-4757 |
0.494 |
|
| 2011 |
Vaughan LS, Barker K, Webber H, Jamin Y, Robinson S, Guichard S, Chesler L. Abstract 4345: AZD8055, a combined TORC1/TORC2 inhibitor regulates Mycn protein expression and prevents neuroblastoma growth in vitro and in vivo Cancer Research. 71: 4345-4345. DOI: 10.1158/1538-7445.Am2011-4345 |
0.48 |
|
| 2011 |
Swartling FJ, Persson AI, Lau J, Northcott PA, Grimmer MR, Chesler L, Perry A, Phillips JJ, Taylor MD, Weiss WA. Abstract 3451: Interactions between N-myc and Sox9 promote medulloblastoma and determine cell fate decisions in cerebellar neural stem cells Cancer Research. 71: 3451-3451. DOI: 10.1158/1538-7445.Am2011-3451 |
0.781 |
|
| 2011 |
Walton MI, Eve PE, Hayes A, Valenti MR, Brandon AKdH, Box G, Hallsworth A, Smith EL, Boxall KJ, Lainchbury M, Matthews TP, Jamin Y, Robinson SP, Aherne GW, Reader JC, ... Chesler L, et al. Abstract A228: CCT244747 is a novel, potent and selective inhibitor of CHK1 with oral efficacy both alone in neuroblastoma and in combination with genotoxic chemotherapeutic agents. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-A228 |
0.466 |
|
| 2010 |
Swartling FJ, Grimmer MR, Hackett CS, Northcott PA, Fan QW, Goldenberg DD, Lau J, Masic S, Nguyen K, Yakovenko S, Zhe XN, Gilmer HC, Collins R, Nagaoka M, Phillips JJ, ... ... Chesler L, et al. Pleiotropic role for MYCN in medulloblastoma. Genes & Development. 24: 1059-72. PMID 20478998 DOI: 10.1101/Gad.1907510 |
0.762 |
|
| 2010 |
Ahmad Z, Moore A, Barker K, Vaughan L, Popov S, Pearson AD, Chesler L. Abstract LB-387: MYCN dependence of tumor propagating cells in an orthotopic model of medulloblastoma Cancer Research. 70. DOI: 10.1158/1538-7445.Am10-Lb-387 |
0.522 |
|
| 2010 |
Vaughan LS, Cullis E, Barker K, Jamin Y, Robinson S, Maira S, Chesler L. Abstract 5255: NVP-BEZ235 a dual PI3K/mTOR inhibitor destabilises Mycn in vitro and is growth inhibitory in the TH-MYCN murine neuroblastoma model Cancer Research. 70: 5255-5255. DOI: 10.1158/1538-7445.Am10-5255 |
0.471 |
|
| 2010 |
Jamin Y, Cullis ER, Vaughan L, Koh D, Chesler L, Robinson SP. Abstract 4189: Characterization of tumor progression and chemoresponse in a novel transgenic mouse model of neuroblastoma (TH-MYCN) using magnetic resonance imaging Cancer Research. 70: 4189-4189. DOI: 10.1158/1538-7445.Am10-4189 |
0.37 |
|
| 2008 |
Chesler L, Goldenberg DD, Collins R, Grimmer M, Kim GE, Tihan T, Nguyen K, Yakovenko S, Matthay KK, Weiss WA. Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction. Neoplasia (New York, N.Y.). 10: 1268-74. PMID 18953436 DOI: 10.1593/Neo.08778 |
0.599 |
|
| 2007 |
Chesler L, Goldenberg DD, Seales IT, Satchi-Fainaro R, Grimmer M, Collins R, Struett C, Nguyen KN, Kim G, Tihan T, Bao Y, Brekken RA, Bergers G, Folkman J, Weiss WA. Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma. Cancer Research. 67: 9435-42. PMID 17909053 DOI: 10.1158/0008-5472.Can-07-1316 |
0.626 |
|
| 2007 |
Meyer GE, Chesler L, Liu D, Gable K, Maddux BA, Goldenberg DD, Youngren JF, Goldfine ID, Weiss WA, Matthay KK, Rosenthal SM. Nordihydroguaiaretic acid inhibits insulin-like growth factor signaling, growth, and survival in human neuroblastoma cells. Journal of Cellular Biochemistry. 102: 1529-41. PMID 17486636 DOI: 10.1002/Jcb.21373 |
0.57 |
|
| 2006 |
Chesler L, Schlieve C, Goldenberg DD, Kenney A, Kim G, McMillan A, Matthay KK, Rowitch D, Weiss WA. Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma Cancer Research. 66: 8139-8146. PMID 16912192 DOI: 10.1158/0008-5472.Can-05-2769 |
0.621 |
|
| 2002 |
Weiss WA, Chesler L. Tumor Models in Cancer Research Drug Discovery Today. 7: 997. DOI: 10.1016/S1359-6446(02)02399-1 |
0.564 |
|
| 1996 |
Volpert OV, Ward WF, Lingen MW, Chesler L, Solt DB, Johnson MD, Molteni A, Polverini PJ, Bouck NP. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats Journal of Clinical Investigation. 98: 671-679. PMID 8698858 DOI: 10.1172/Jci118838 |
0.367 |
|
| 1995 |
Chesler L, Golde D, Bersch N, Johnson. Metalloproteinase inhibition and erythroid potentiation are independent activities of tissue inhibitor of metalloproteinases-1. Blood. 86: 4506-4515. DOI: 10.1182/Blood.V86.12.4506.Bloodjournal86124506 |
0.308 |
|
| 1994 |
Johnson MD, Kim HC, Chesler L, Tsao‐Wu G, Polverini PJ, Bouck N. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase. Journal of Cellular Physiology. 160: 194-202. PMID 7517405 DOI: 10.1002/Jcp.1041600122 |
0.34 |
|
| Show low-probability matches. |